Companies /Healthcare

Delcath Systems Inc

NASDAQ: DCTH Medical Devices
$19.37
▼ $0.50 (−2.52%) today
Markets closed · 5:37pm ET

DCTH at a Glance

Valuation
Market cap
$691.2M
P/E ratio
124.2
Profitability
Revenue (TTM)
$110.0M
Profit margin
6.1%
EPS (TTM)
$0.16
Price
52-week range
$8 – $23
Street target
$28.60

Headquartered in Queensbury, NY Fiscal year ends December NASDAQ: DCTH delcath.com

About Delcath Systems

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Its proprietary products are designed to deliver high-dose chemotherapy directly to the liver through percutaneous hepatic perfusion (PHP) while controlling systemic exposure and associated side effects.

The products are:
- **HEPZATO KIT** (HEPZATO (melphalan) for Injection/Hepatic Delivery System): sold in the United States.
- **CHEMOSAT Hepatic Delivery System for Melphalan**: sold in Europe.

In the U.S., HEPZATO KIT is a drug-device combination product regulated and approved by the FDA as a drug, and it carries a boxed warning. It combines the chemotherapeutic melphalan with Delcath's Hepatic Delivery System (HDS). The HDS isolates hepatic venous blood from the systemic circulation and filters it during melphalan infusion and washout. HEPZATO KIT is approved for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver, with limited or resectable extrahepatic disease.

In Europe, the device-only HDS is regulated as a Class III medical device and sold as CHEMOSAT. It is used at major medical centers to treat a range of liver cancers.

The company generates revenue primarily from HEPZATO KIT sales to a network of U.S. treatment centers, currently 33 active centers. It is expanding into new indications:
- The global Phase 2 DELUMA trial in liver-dominant HER2-negative metastatic breast cancer.
- A planned IND for cholangiocarcinoma in early 2027.
- An oxaliplatin-based PHP product in preclinical development. Updated

DCTH Coverage

6:20am ET
Investing

The 6 Most Shorted Nasdaq Stocks

Short sellers shied away from the two most shorted stocks traded on the Nasdaq between the latest settlement dates, but they moved on other short seller favorites.

Trey Thoelcke
4:27pm ET
Investing

Stock Market Today: Big Winners & Losers for Tuesday

thinkstockHere are the five biggest gaining stocks in today’s U.S. markets at closing: Transition Therapeutics Inc. (NASDAQ: TTHI) is up 37.8% at $3.10. Digital Ally Inc. (NASDAQ: DGLY) is up 35.8% at…

Paul Ausick
1:45pm ET
Investing

5 Unusual Low-Priced Major Volume Spikes

ThinkstockLow-priced stocks can often have active volume already, and quite often due to perhaps nothing more than their low share price when news is announced. 24/7 Wall St. already tracked the active…

Jon C. Ogg
10:27am ET
Investing

Today’s Market Winners and Losers

Photo by Spencer Platt/Getty ImagesThe stock market is mixed Monday, with the Dow Jones Industrial Average up 0.06%, the Nasdaq down 0.09% and the S&P 500 flat. Today’s big winner is a…

247sam

Frequently Asked Questions

What does Delcath Systems do?

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

What is the DCTH stock price target?

The Wall Street consensus 12-month price target for DCTH is $28.60.